ABSTRACT
Despite the notable clinical impact, recent molecular epidemiology regarding third-generation cephalosporin-resistant Klebsiella pneumoniae (3GC-RKp) in the United States remains limited. We performed whole genome sequencing of 3GC-RKp bacteremia isolates collected from March 2016 to May 2022 at a tertiary care cancer center in Houston, TX using Illumina and Oxford Nanopore Technologies platforms. A comprehensive comparative genomic analysis was performed to dissect population structure, transmission dynamics, and pan-genomic signatures of our 3GC-RKp population. Of the 194 3GC-RKp bacteremias that occurred during our study timeframe, we were able to analyze 153 (79%) bacteremia isolates, 126 initial and 27 recurrent isolates respectively. While isolates belonging to the widely prevalent clonal group (CG) 258 were rarely observed, the predominant clonal group, CG307, accounted for 37 (29%) index isolates and displayed a significant correlation (Pearson correlation test P-value = 0.03) with the annual frequency of 3GC-RKp bacteremia. Within our CG307 cohort, 89% (33/37) of our isolates belong to the global rather than previously described Texas-specific clade. Strikingly, we identified a new CG307 sub-clade (i.e., cluster 1 isolates) comprised of 18 isolates characterized by the chromosomally-encoded blaSHV-205 and unique accessory genome content. This CG307 sub-clade was detected in various United States regions, with genome sequences from 24 additional strains becoming recently available in the NCBI SRA database. Collectively, this study underscores the emergence and dissemination of a distinct CG307 sub-clade that is a prevalent cause of 3GC-RKp bacteremia among cancer patients seen in Houston, TX and has recently been isolated throughout the United States.
DATA SUMMARY WGS data sequenced during this study period was submitted to NCBI and can be accessed within BioProject PRJNA648389. WGS data from previous study of carbapenem non-susceptible Enterobacterales can be accessed from BioProject PRJNA836696. Assembly information and BioAccession numbers are provided in Table S1.
IMPACT STATEMENT Infections due to 3rd generation cephalosporin resistant Klebsiella pneumoniae (3GC-RKp) are considered among the most urgent public health threats. However, molecular epidemiology studies on 3GC-RKp in the United States are limited. Our analysis indicates a preponderance of genetically diverse 3GC-RKp isolates harboring the key antimicrobial resistance determinant blaCTX-M-15 at our institution. Importantly, however, we detected evidence of long duration transmission of highly genetically related CG307 and CG29 specific clusters at our institution. Interestingly, we rarely detected the pandemic CG258 lineage in our cohort and did not detect more than two genetically related CG258 isolates from this lineage. We found that 90% of our isolates from the most prevalent clonal group, CG307, belonged to a novel, nested-population of a “global” CG307 clade in contrast to the more commonly detected “Texas-specific” clade that has circulated in our region. We searched the NCBI SRA database using genomic markers of the novel CG307 clade and found evidence of this clade causing recent invasive infections in other locations across the United States. Our study highlights the shifting population dynamics of K. pneumoniae causing invasive infections and the necessity to continue AMR surveillance in order to identify emerging high-risk populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Core grant CA016672(ATGC) and NIH 1S10OD024977-01 grant provide funding for the Advanced Technology Genomics Core (ATGC) sequencing facility at MD Anderson Cancer Center. SSA was supported by Dell Family Fund for the School of Health Professional scholarship and CTW is supported by Peter and Cynthia Hu scholarship. WCS is supported through the National Institute of Allergy and Infectious Diseases (NIAID) T32 AI141349 Training Program in Antimicrobial Resistance. Support for this study was also provided by the NIAID R21AI151536 and P01AI152999 for S.A.S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This surveillance study has received ethical approval through the University of Texas MD Anderson Cancer Center (MDACC) Institutional Review Board (Protocol ID: PA13-0334).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors